Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-MEL050 is a fluorine-18 labeled radiopharmaceutical designed as a positron emission tomography (PET) imaging agent for the specific detection of melanin-containing tissues. It belongs to the class of benzamide derivatives, which exhibit high affinity and selectivity for melanin pigments. The mechanism of action involves the tracer binding to melanin within melanocytes, allowing for high-contrast visualization of primary and metastatic melanotic melanoma. Developed primarily for oncology applications, 18F-MEL050 aims to improve the staging and monitoring of melanoma patients, particularly in cases where standard FDG-PET may be less specific or where precise localization of melanotic lesions is required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-MEL050.